ESC 2024：聚焦肺动脉高压，探索先进诊断与个性化管理新前沿
健康
健康
2024-08-13 17:10
北京
肺动脉高压（pulmonary hypertension，PH）是一组多因素引起的疾病，其特征是在静息状态下肺动脉平均压（mPAP）升高。值得注意的是，即使是轻度肺动脉高压，也与增加的死亡风险以及过早的死亡风险相关。然而，这一疾病往往隐匿且难以察觉，许多患者直至病情晚期才得以诊断。鉴于肺动脉高压的诊断和管理挑战，今年的ESC大会将通过摘要报告、研讨会、电子海报以及与欧洲呼吸学会的联席会议等多种形式，深入探讨肺动脉高压的先进诊断技术、个性化管理全过程、最新药物治疗进展以及其未来管理的方向。让我们共同关注即将在ESC 2024（欧洲心脏病学会年会）上展开的关于肺动脉高压的核心议题与重要议程，以期更全面地了解这一领域的最新进展与未来趋势。Pulmonary hypertension: advanced diagnosticsMultiscan-PH: a multimodal deep learning approach for enhanced screening of pulmonary hypertensionMultiscan-PH：一种用于增强肺动脉高压筛查的多模态深度学习方法Circulating Angiopoietin-2 (Angpt2) levels predict diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)循环血管生成素-2（Angpt2）水平预测慢性血栓栓塞性肺动脉高压（CTEPH）的诊断TAPSE/sPAP by echocardiography to detect elevated pulmonary vascular resistance> 4 WU in postcapillary pulmonary hypertension patients: insights from the French PH HF registry通过超声心动图检测TAPSE）/sPAP，以检测毛细血管后肺动脉高压患者的肺血管阻力升高（>4WU）：来自法国PH HF登记处的见解Advancing pulmonary hypertension early detection through deep-learning enhanced chest radiographic analysis通过深度学习增强的胸部X光分析推进肺动脉高压的早期检测Assessment of sub clinical right ventricular ischemia using oxygen sensitive cardiac magnetic resonance imaging in patients with systemic sclerosis: mechanistic insights from advanced cardiac imaging使用氧敏心脏磁共振成像评估系统性硬化症患者亚临床右心室缺血：来自高级心脏成像的机制见解The pregnant patient with pulmonary arterial hypertensionand her offspring in the current era. Time to take into account the vasoreactive profile当今时代肺动脉高压孕妇及其后代：是时候考虑血管反应性特征了Right atrial and ventricular function in risk stratification of patients with pulmonary artery hypertensionRKER-012, a novel modified ActRIIB ligand trap, attenuated right ventricular cardiomyopathy in a preclinical model of pulmonary arterial hypertensionRKER-012，一种新型改良的ActRIIB配体陷阱，在肺动脉高压临床前模型中减轻了右心室心肌病The impact of the 2022 definition of pulmonary hypertension on long-term clinical outcomes in patients with heart failure with preserved ejection fraction2022年肺动脉高压定义对射血分数保留的心力衰竭患者长期临床结果的影响Parathyroid hormone exacerbates pulmonary hypertension via parathyroid hormone receptors on pulmonary artery smooth muscle cells甲状旁腺激素通过肺动脉平滑肌细胞上的甲状旁腺激素受体加重肺动脉高压
Pulmonary hypertension: from diagnosis to personalised careWhat’s hot in pulmonary hypertension?Not all pulmonary arterial hypertension (PAH) patients are young womenObesity and pulmonary hypertensionPersonalising treatment of chronic thromboembolic pulmonary hypertension (CTEPH): right treatment for the right patient慢性血栓栓塞性肺动脉高压（CTEPH）的个性化治疗：为合适的患者提供正确的治疗Pulmonary hypertension: from diagnosis to personalised care - discussionOfficial Joint Session
与欧洲呼吸学会的联席会议
Shaping the future management of pulmonary hypertensionInclusion of the patient perspective in new trials in pulmonary hypertensionNovel concepts in trial design: a trialist's viewWill omics finally fulfil the promise of personalised medicine in pulmonary hypertension?What is the state of the art of reverse remodelling strategies for the treatment of pulmonary arterial hypertension?
Association of Vascular endothelial factor D with pulmonary hypertension in heart failure: the PREHOSP-CHF Study血管内皮因子 D 与心力衰竭肺动脉高压的关联：PREHOSP-CHF 研究Novel CMR-assessed right ventricular-pulmonary artery coupling index independently associates with exercise capacity and clinical risk in pulmonary arterial hypertension新型 CMR 评估的右心室-肺动脉耦合指数与肺动脉高压的运动能力和临床风险独立相关Pulmonary hypertension: insights from registries, retrospective data sets, and meta-analyses肺动脉高压：来自注册机构、回顾性数据集和荟萃分析的见解Improving morbidity and mortality in patients with pulmonary hypertension: insights from a nation-wide registry改善肺动脉高压患者的发病率和死亡率：来自全国登记处的见解Real-world evidence on pulmonary arterial hypertension: interim analysis from the Italian observational study INSPECTIO肺动脉高压的真实世界证据：来自意大利观察性研究 INSPECTIO 的中期分析Idiopathic pulmonary arterial hypertension, associated with connective tissue disease and comorbidities: prognostic differences? Results the Spanish Registry of pulmonary hypertension (REHAP Registry)特发性肺动脉高压，与结缔组织疾病和合并症有关：预后差异？西班牙肺动脉高压登记册（REHAP登记册）的结果Clinical, echocardiographic and haemodynamic predictors of morbidity and mortality in pulmonary hypertension: a nation-wide registry肺动脉高压发病率和死亡率的临床、超声心动图和血流动力学预测指标：一项全国性登记研究The importance of comorbidities in idiopathic and associated with connective tissue disease pulmonary arterial hypertension: from the Spanish Registry of Pulmonary Hypertension (REHAP Registry)合并症在特发性肺动脉高压和与结缔组织疾病相关的肺动脉高压中的重要性：来自西班牙肺动脉高压登记处的数据A systematic review and meta-analysis of health-related quality of life (HRQoL) outcomes in randomised controlled trials for pulmonary arterial hypertension (PAH)肺动脉高压随机对照试验中健康相关生活质量（HRQoL）结果的系统评价和荟萃分析Changing patterns in clinical, echocardiographic and haemodynamic characteristics , and management strategies that may be translated to improved survival in pulmonary hypertension改变临床、超声心动图和血流动力学特征的模式，以及可能转化为提高肺动脉高压生存率的管理策略Risk prediction and survival in elderly patients with pulmonary arterial hypertension: data from the hellenic pulmonary hypertension registry (HOPE)老年肺动脉高压患者的风险预测和生存：来自希腊肺动脉高压登记处（HOPE）的数据Mini nutritional assessment is a predictor of mortality and morbidity in patients with pulmonary arterial hypertension微型营养评估是肺动脉高压患者死亡率和发病率的一个预测指标Colchicine as a therapeutic option for the treatment of pulmonary arterial hypertension (PAH) in a rat model秋水仙碱作为大鼠模型中肺动脉高压（PAH）治疗的选择Current pharmacological treatments for pulmonary hypertensionEffects of beta blockers on outcome in patients with PAH with and without comorbid conditions: a Multicenter Prospective Cohort Study (BNP-PL)β阻滞剂对有和没有合并症的PAH患者预后的影响：一项多中心前瞻性队列研究（BNP-PL）Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertensionARNI和SGLT2i联合用药对三尖瓣反流峰值速度和肺动脉高压超声心动图可能性的影响The safety and efficacy of treprostinil for the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials曲前列尼尔治疗肺动脉高压的安全性和有效性：随机对照试验的系统评价和荟萃分析Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre studyselexipag 三联序贯联合疗法在肺动脉高压患者中的疗效和耐受性：来自单中心研究的见解Metoprolol therapy in patients with Eisenmenger syndrome (MINES) study. A single-centre, double-blinded, randomised, placebo-controlled trial艾森曼格综合征（MINES）患者的美托洛尔治疗研究：一项单中心、双盲、随机、安慰剂对照试验Real-world evidence of upfront riociguat plus endothelin receptor antagonist combination therapy in pulmonary arterial hypertension肺动脉高压患者使用利奥西呱联合内皮素受体拮抗剂组合疗法的真实世界证据Efficacy of specific drug class therapy in pulmonary arterial hypertension associated with HIV, portal hypertension or both: a single Center experience特定药物类别治疗HIV相关肺动脉高压、门静脉高压或两者兼有患者的疗效：单中心经验Cardiopulmonary exercise testing in long-term calcium channel blockers responders, does it normalize in the same way as pulmonary vascular resistance?长期钙通道阻滞剂应答者的心肺运动试验，是否与肺血管阻力相同？Positioning Imatinib for Pulmonary Arterial Hypertension (PIPAH) studyImpact of new definition on the prognosis of patients with pulmonary hypertension compared to classic definitionA novel nurse-led, multidisciplinary, and guideline-directed disease intensive management program improves long-term survival of pulmonary hypertension patients一项由护士主导、多学科合作、遵循指南的疾病强化管理计划改善了肺动脉高压患者的长期生存率
![]()
声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
凡原创文章版权属《国际循环》所有。欢迎个人转发分享。其他任何媒体、网站如需转载或引用本网版权所有之内容须在醒目位置处注明“转自《国际循环》”
![]()
